Esperion Logo (primary).png
Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
May 04, 2017 16:05 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Logo (primary).png
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
March 20, 2017 07:30 ET | Esperion Therapeutics, Inc.
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those...
Esperion Logo (primary).png
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
March 07, 2017 08:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...
Esperion Logo (primary).png
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
January 08, 2017 16:00 ET | Esperion Therapeutics, Inc.
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on...
Esperion Logo (primary).png
Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017 17:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...
Esperion Logo (primary).png
Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
November 28, 2016 16:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of...
Esperion Logo (primary).png
Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
November 09, 2016 16:30 ET | Esperion Therapeutics, Inc.
Presentation and Webcast on Wednesday, November 16, 2016 at 3:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical...
Esperion Logo (primary).png
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
November 03, 2016 16:05 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...
Esperion Logo (primary).png
Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
November 01, 2016 16:30 ET | Esperion Therapeutics, Inc.
Presentation and Webcast on Tuesday, November 8, 2016 at 3:00 p.m. Pacific Time/6:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....
Esperion Logo (primary).png
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...